Other methods of targeting KRAS-mutated cancers are using pan-pathway inhibitors, most commonly targeting the downstream MAPK molecule MEK, with enhanced efficacy with combination therapy targeting the EGFR, CDK, JAK/STAT, PI3K pathways with a KRAS inhibitor. Here, KRAS is linked to cancer.